Introduction Menstrual migraine affects over 15 million women across the seven major pharmaceutical markets. At present the disease is managed using a wide variety of pharmacological treatments. However, none of these compounds have an indication specifically for menstrual migraine. With the market relatively untapped, it presents an abundance of commercial opportunities for pharmaceutical manufacturers.
Scope - Overview of epidemiology data and patient potential of the menstrual migraine market
- Evaluation of current treatments and key unmet needs
- Therapeutic and market potential of compounds in clinical trials
- Commercial opportunities for compounds currently being used off-label
Report Highlights Pharmaceutical manufacturers competing in the migraine market should adopt the standardized definition of menstrual migraine proposed by the International Headache Society.
Research and development should focus on compounds that address unmet needs such as migraine specific compounds, short-term prophylactic therapies, treatment refractory patients, and quicker onset of action.
Extensive placebo-controlled trials should be initiated to provide robust data showing the true clinical advantages of medications ( i.e. triptans) for menstrual migraine. Other drug manufacturers with anticonvulsant and antidepressant therapies should position their products as an alternative treatment for menstrual migraine.
Reasons to Purchase - Assess the patient potential of the menstrual migraine market
- Identify the level of unmet need and subsequent market opportunities
- Evaluate the therapeutic potential of compounds in clinical trials
